Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia (CHoPA-I)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00767091

Recruitment Status : Completed

First Posted : October 6, 2008

Last Update Posted : April 24, 2012

View this study on Beta.ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

University Hospital, Lille

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	December 2011
Actual Study Completion Date :	January 2012

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Devos D, Moreau C, Maltete D, Lefaucheur R, Kreisler A, Eusebio A, Defer G, Ouk T, Azulay JP, Krystkowiak P, Witjas T, Delliaux M, Destee A, Duhamel A, Bordet R, Defebvre L, Dujardin K. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):668-74. doi: 10.1136/jnnp-2013-306439. Epub 2013 Nov 11.

To Top